Centogene N.V. (CNTG)
| Previous Close | 2.1100 |
| Open | 2.4100 |
| Bid | 2.0700 x 1000 |
| Ask | 2.3900 x 1100 |
| Day's Range | 2.1100 - 2.4300 |
| 52 Week Range | 1.8300 - 11.9500 |
| Volume | |
| Avg. Volume | 9,303 |
| Market Cap | 54.702M |
| Beta (5Y Monthly) | -1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5920 |
| Earnings Date | Apr 13, 2022 - Apr 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.99 |
- GlobeNewswire
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 13, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the comme
- Zacks
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Change Healthcare (CHNG) Q4 Earnings Miss Estimates
Change Healthcare (CHNG) delivered earnings and revenue surprises of -9.30% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
